Lipoxin A4 as a possible mediator of the beneficial actions of phosphodiesterase-5 enzyme inhibitors

Lipoxin A4 as a possible mediator of the beneficial actions of phosphodiesterase-5 enzyme inhibitors

Bibliographic Details
Main Author:	Undurti N. Das
Format:	Article
Language:	English
Published:	Termedia Publishing House 2016-12-01
Series:	Archives of Medical Science
Online Access:	https://www.termedia.pl/Lipoxin-A4-as-a-possible-mediator-of-the-beneficial-actions-of-phosphodiesterase-5-enzyme-inhibitors,19,28942,1,1.html

Similar Items

Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
by: Mauro Giorgi, et al.
Published: (2020-07-01)

Beneficial effects of certain phosphodiesterase inhibitors on diabetes mellitus in rats
by: Mostafa El Sayed El Sayed, et al.
Published: (2014-12-01)

Study Of Role Of Lipoxin – A4 In Psoriasis
by: Hanan Al Nemr, et al.
Published: (2022-01-01)

Mechanisms in anti-inflammation and resolution: the role of lipoxins and aspirin-triggered lipoxins
by: Fierro I.M., et al.
Published: (2001-01-01)

Repurposing Phosphodiesterase-5 inhibitors as chemoadjuvants
by: Amit K. Tiwari, et al.
Published: (2013-06-01)

Synthesis of aromatic lactone analogues of Lipoxin A4
by: Aya Ismael, et al.
Published: (2022-02-01)

Phosphodiesterase type 5 inhibitor (Levitra): possibility of correction of erectile dysfunction in obese patients
Published: (2008-03-01)

Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions
by: Byung Woo Kang, et al.
Published: (2022-07-01)

Simvastatin and Benznidazole-Mediated Prevention of Trypanosoma cruzi-Induced Endothelial Activation: Role of 15-epi-lipoxin A4 in the Action of Simvastatin.
by: Carolina Campos-Estrada, et al.
Published: (2015-05-01)

Lipoxin-mediated signaling: ALX/FPR2 interaction and beyond
by: Sergio Sánchez-García, et al.
Published: (2023-11-01)

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
by: Heng Li, et al.
Published: (2018-10-01)

Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis
by: Viera Janosova, et al.
Published: (2020-07-01)

Urinary lipoxin A4 as a biomarker for systemic lupus erythematosus
by: Manal M Sedky Abdou, et al.
Published: (2015-01-01)

Evaluation of the Therapeutic Index of a Novel Phosphodiesterase 4B– Selective Inhibitor Over Phosphodiesterase 4D in Mice
by: Osamu Suzuki, et al.
Published: (2013-01-01)

The effect of Lipoxin A<sub>4 </sub>on the interaction between macrophage and osteoblast: possible role in the treatment of aseptic loosening
by: Sun Li, et al.
Published: (2009-06-01)

Increased lipoxin B4 levels in children with atopic dermatitis
by: Himmet Haluk Akar, et al.
Published: (2019-10-01)

Phosphodiesterase-4 inhibitor in the treatment of psoriasis and psoriatic arthritis
by: O. Yu. Olisova, et al.
Published: (2019-07-01)

Use of phosphodiesterase 4 inhibitor in patients with psoriatic arthritis
by: V. I. Mazurov, et al.
Published: (2017-04-01)

Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases
by: Theerasuk Kawamatawong
Published: (2021-08-01)

Roflumilast: Review of Phosphodiesterase-4 Inhibitor as Asthma Therapy
by: Rafina Syfridiana, et al.
Published: (2021-08-01)

The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice.
by: Florian Rieder, et al.
Published: (2013-01-01)

Glucocorticoid Exposure Induces Preeclampsia via DampeningLipoxin A4, an Endogenous Anti-Inflammatory and Proresolving Mediator
by: Haojing Liu, et al.
Published: (2020-07-01)

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
by: Oana Ramona Cătălina Gheorghiu, et al.
Published: (2023-05-01)

Lipoxins and aspirin-triggered lipoxin alleviate bone cancer pain in association with suppressing expression of spinal proinflammatory cytokines
by: Hu Shan, et al.
Published: (2012-12-01)

Beneficial role of bioactive lipids in the pathobiology, prevention, and management of HBV, HCV and alcoholic hepatitis, NAFLD, and liver cirrhosis: A review
by: Undurti N. Das
Published: (2019-05-01)

The role of phosphodiesterase 4B in IL-8/LTB4-induced human neutrophil chemotaxis evaluated with a phosphodiesterase 4B inhibitor
by: Suzuki Osamu, et al.
Published: (2015-06-01)

Phosphodiesterase Inhibitors: Present and Future
by: José L. Izquierdo-Alonso
Published: (2023-01-01)

Effect of phosphodiesterase inhibitors in the bladder
by: Bilal Chughtai, et al.
Published: (2015-01-01)

Beneficial Actions of Essential Fatty Acids in Streptozotocin-Induced Type 1 Diabetes Mellitus
by: Junhui Shen, et al.
Published: (2022-05-01)

Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives
by: Ahmed K. ElHady, et al.
Published: (2023-09-01)

Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver
by: Dunkern Torsten, et al.
Published: (2009-09-01)

A mosquito lipoxin/lipocalin complex mediates innate immune priming in Anopheles gambiae
by: Jose Luis Ramirez, et al.
Published: (2015-06-01)

Natural Products and Their Derivatives as Inhibitors of the DNA Repair Enzyme Tyrosyl-DNA Phosphodiesterase 1
by: Alexandra L. Zakharenko, et al.
Published: (2023-03-01)

Lipoxin A₄ and 15-epi-lipoxin A₄ protect against experimental cerebral malaria by inhibiting IL-12/IFN-γ in the brain.
by: Nathaniel Shryock, et al.
Published: (2013-01-01)

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
by: Jonathan E. Phillips
Published: (2020-03-01)

Angiotensin-converting enzyme inhibitors and angiotensin receptor blocker in coronavirus disease 2019: Safe and possibly beneficial
by: Nitesh Gupta, et al.
Published: (2020-01-01)

The place of a phosphodiesterase 4 inhibitor in the treatment strategy for psoriatic arthritis
by: V. I. Mazurov, et al.
Published: (2018-04-01)

Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules
by: Das Undurti N
Published: (2008-10-01)

The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter.
by: Pei-Rong Ding, et al.
Published: (2011-04-01)

A Non-Systemic Phosphodiesterase-5 Inhibitor Suppresses Colon Proliferation in Mice
by: Avelina Lee, et al.
Published: (2023-05-01)